Skip to Main Content

Try STAT+ TODAY

venture capital

Most Read

Biotech Allison DeAngelis

STAT Plus: Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight

The Readout LOUD Damian Garde and Allison DeAngelis

Fauci’s non-retirement, grading biotech VCs, & a bellwether IPO

Biotech Kate Sheridan

STAT Plus: OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking

Biotech Kate Sheridan

STAT Plus: Private equity giant Carlyle to acquire biotech venture capital firm Abingworth

Business Meghana Keshavan

There’s just one female CEO among San Diego’s public biotechs. Here’s why

Business Rebecca Robbins

The market for microbiome therapies is booming. Meet the latest entrant

First Opinion Paul J. Hastings

STAT Plus: The lesson biotech absolutely should not take from Silicon Valley Bank’s failure

Biotech Allison DeAngelis and Matthew Herper

STAT Plus: With $520 million in hand, two entrepreneurs try to upend the biotech funding model

All Coverage

First Opinion Barbara Handelin and Sandra Heibel

STAT Plus: Why the U.S. needs a public benefit biopharma industry

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

advertisement

First Opinion Steve Brozak

Theranos debacle may scare investors away from diagnostic technology

Business Rebecca Robbins

Balding heads. Buzzwords. Biotech execs refine the art of the pitch

Business Andrew Joseph

Companies seek to diagnose cancer from a blood sample